The Continuous Tracheal Gas Insufflation (CTGI) is a ventilation option of conventional mechanical ventilation that is used to reduce or even eliminate the dead space caused by respiratory prostheses. This objective is of particular interest in the smallest preterm infants, where the volume of anatomical dead space due to prostheses is little different from the tidal volume. The principle of this option is to continuously blow an additional flow of 0.2 L/minute at the tip of the endotracheal tube to purge expired CO2 trapped in the prostheses, to have a CO2-free volume of gas available for subsequent insufflation. The goal of this clinical trial is to learn if Continuous Tracheal Gas Insufflation (CTGI) works to reduce ventilatory dependence in preterm infants after mechanical ventilation. It will also learn about the safety of CTGI. The main questions it aims to answer are: * Does Continuous Tracheal Gas Insufflation (CTGI) reduce the number of days of non-invasive ventilation in extremely preterm infants who needed mechanical ventilation? * Does Continuous Tracheal Gas Insufflation (CTGI) reduce the age at the weaning of any ventilatory support and/or oxygen supplementation. Researchers will compare the clinical outcome of patients mechanically ventilated with the CTGI-device to the outcome of patients ventilated without the CTGI device, to see if the CTGI ventilation works to reduce ventilation dependence. Participants will: • Be mechanically ventilated using CTGI (if randomly assigned in the CTGI-group), for the entire endotracheal ventilation period during their stay in the neonatal intensive care unit.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
144
The intervention involves adding a device which allows CTGI (the "CTGI-device") to washout the dead space in preterm mechanically ventilated infants. Dead space washout using the CTGI-device is an option added to standard ventilation, to reduce or even cancel anatomical dead space due to respiratory prostheses in intubated preterm infants.
Centre Hospitalier Intercommunal de Creteil
Créteil, France
Centre Hospitalier Universitaire de Nantes
Nantes, France
Centre Hopistalier Universitaire Cochin Port Royal aphp
Paris, France
Centre hospitalier Robert Debré aphp
Paris, France
Cumulative duration of all periods of non-invasive ventilation
The cumulative duration of all periods of non-invasive ventilation, in days, starting from birth, and up to maximum 45 weeks corrected gestational age. Non-invasive ventilation includes all types of positive pressure support non-invasive ventilation and high flow nasal cannula ventilation (HFNC).
Time frame: From birth to the end of hospital stay, up to maximum 45 weeks of corrected gestational age.
Number of participants deceased
For each arm: mortality rate during initial hospitalization.
Time frame: From enrollment to the date of the end of the hospital stay, up to maximum 5 months of life
Measure of the Driving Pressure during mechanical ventilation
Mean Driving pressure (∆P: Ppeak-PEEP) collected each 12 hours for all patients on invasive mechanical ventilation.
Time frame: From enrollment to the date of the end of the hospital stay, up to maximum 5 months of life
Measure of expiratory tidal volume during mechanical ventilation.
Mean expiratory tidal volume (VT) collected each 12 hours for all patients on invasive mechanical ventilation.
Time frame: From enrollment to the date of the end of the hospital stay, up to maximum 5 months of life
Measure of carbon dioxide partial pressure (PCO2) on blood gas
Carbon dioxide partial pressure (PCO2) on patient's blood gas during mechanical ventilation
Time frame: From enrollment up to maximum 15 days of life
Measure of Transcutaneous Carbon dioxide partial pressure (TcPCO2)
Transcutaneous measure of Carbon dioxide partial pressure (TcPCO2) collected each 12 hours during mechanical ventilation.
Time frame: From enrollment to the date of the end of the hospital stay, up to maximum 5 months of life
Number of participants who received a second dose of surfactant
Rates of patients with more than one dose of surfactant replacement therapy.
Time frame: From birth up to maximum 7 days of life.
Number of participants treated with high-frequency ventilation (HFV) or high-frequency oscillatory ventilation (HFOV).
Rates of patients treated with High Frequency ventilation (HFV) or High frequency oscillatory ventilation (HFOV) during invasive mechanical ventilation.
Time frame: From enrollment to the date of the end of the hospital stay, up to maximum 5 months of life
Use of Inhaled Nitric Oxide (iNO therapy)
Rates of patients treated with nitric oxyde (iNO) during invasive mechanical ventilation.
Time frame: From enrollment to the date of the end of the hospital stay, up to maximum 5 months of life
Number of participant with Severe hypoxemia
Rates of patients with Oxygenation Index ≥ 10
Time frame: From enrollment to the date of the end of the hospital stay, up to maximum 5 months of life
Number of participants treated for Pneumothorax
Rates of patients with treated Pneumothorax (Needle Thoracentesis or Chest Drainage)
Time frame: From enrollment to the date of the end of the hospital stay, up to maximum 5 months of life
Number of participants treated with Systemic Corticosteroids for Prevention or Management of Bronchopulmonary Dysplasia (BPD)
Rates of patients treated with systemic corticosteroids for the prevention or management of BPD and number of days of treatment, excluding prophylactic hydrocortisone treatment in the first 10 days of life.
Time frame: From enrollment to the date of the end of the hospital stay, up to maximum 5 months of life
Number of participants diagnosed as Bronchopulmonary Dysplasia (BPD)
Rates of patients with Bronchopulmonary Dysplasia (BPD) diagnosed at 36 weeks of corrected gestational age.
Time frame: From two days before 36 weeks of corrected gestational age until two days after 36 weeks of corrected gestational age..
Number of participants with unplanned extubation
Rates of unplanned extubations per 100 ventilator days, and context.
Time frame: From birth to the date of the end of the hospital stay, up to maximum 5 months of life
Calculation of days with invasive mechanical ventilation for each participant.
Number of days spent on invasive mechanical ventilation
Time frame: From birth to the date of the end of the hospital stay, up to maximum 5 months of life
Calculation of the mean age at definitive weaning from invasive ventilation for the participants in each arm.
Age at total weaning from invasive mechanical ventilation
Time frame: From birth to the date of the end of the hospital stay, up to maximum 5 months of life
Age of participants at definitive weaning from all positive pressure ventilatory support
The age in days when the infant is definitively weaned from invasive and non-invasive positive pressure ventilation, excluding High Flow Nasal Canula (HFNC) and Low Flow Nasal Canula ventilation (LFNC).
Time frame: From birth to the date of the end of the hospital stay, up to maximum 5 months of life
Age of the participants at the definitive withdrawal of any Ventilatory Support
The age in days when the infant is definitively weaned from invasive and non-invasive ventilation, including High-Flow Nasal Cannula (HFNC). This excludes Low-Flow Nasal Cannula (LFNC), with or without supplemental oxygen delivery.
Time frame: From birth to the date of the end of the hospital stay, up to maximum 5 months of life
Age of the participants at definitive O2 weaning.
The age in days when the patient is definitively weaned from oxygen supplementation. This includes being weaned from any respiratory support system, as well as from Low-Flow Nasal Cannula, with or without supplemental oxygen delivery.
Time frame: From birth to the date of the end of the hospital stay, up to maximum 5 months of life
Number of participants with Late-onset primary bloodstream infections
Rates of Late-onset primary bloodstream infections using CDC surveillance definitions, calculated for 1000 central-line days.
Time frame: From birth to the date of the end of the hospital stay, up to maximum 5 months of life
Number of participants with Neuroimaging complications
Rates of acquired neuroimaging complications: Periventicular Leucomalacia, Cerebellar haemorrhage, Intra-Ventricular Haemorrhage Grade 3 and 4.
Time frame: From birth to the date of the end of the hospital stay, up to maximum 5 months of life
Number of participants Treated for Retinopathy (ROP)
Rates of Retinopathy (ROP) receiving either retinal laser or intravitreal anti-VEGF therapy.
Time frame: From birth to the date of the end of the hospital stay, up to maximum 5 months of life
Number of days for each participant of Exposure to systemic analgesic or sedatives treatments
Number of days with systemic analgesic or sedative treatments.
Time frame: From birth to the date of the end of the hospital stay, up to maximum 5 months of life
First cytokine dosage in tracheal aspirates.
Mean Cytokines dosage from tracheal aspirates in intubated patients (one unique aspiration). This outcome will be assessed only for patients enrolled in the study and on mechanical ventilation between 24 and 48 hours of life.
Time frame: Between 24 hours to 48 hours of life.
Second cytokine dosage in tracheal aspirates.
Mean Cytokines dosage from tracheal aspirates in intubated patients (one unique aspiration). This outcomes will be assessed only for patients enrolled in the study and on mechanical ventilation between day 4 and 5 of life.
Time frame: Between day 4 to day 5 of life.
Third cytokine dosage in tracheal aspirates.
Mean Cytokines dosage from tracheal aspirates in intubated patients. This outcomes will be assessed only for patients enrolled in the study and on mechanical ventilation between day 10 and day 12 of life.
Time frame: Between day 10 to day 12 of life.
Number of participants requiring hemodynamic support.
Rates of patients receiving hemodynamic support during their hospital stay (systemic catecholamines, volume expansion).
Time frame: From enrollment in the study to the date of the end of the hospital stay, up to maximum 5 months of life
Measurement of average weight gain for all study participants in each arm.
Weight gain in grams between birth weight and weight at 36 weeks of corrected gestational age.
Time frame: From birth to the date of 36 weeks of corrected gestational age.
Number of days for each participant in the study with central venous line
Addition of all the periods the patients has a central line, in days.
Time frame: From birth to the date of the end of the hospital stay, up to maximum 5 months of life
Resuts of Neurodevelopmental Follow-up for surviving participants.
Results of the validated French version of the "Ages \& stages questionnaires" (ASQ3), a developmental screening tool based on parental reporting for their child. This tool will be sent to the parents, and collected.
Time frame: At 2 years of corrected age (± 2 months)
Number of participants with Cerebral Palsy
Rates of patients with cerebral palsy.
Time frame: At 2 years of corrected age (± 2 months)
Number of participants with visual disorders at 2 years of age
Rates of patients with severe visual disorders defined as a need for glasses at 2 years of corrected age (± 2 months)
Time frame: At 2 years of corrected age (± 2 months)
Number of participants necessitating respiratory drugs during the two first years of life.
Rates of patients with respiratory symptoms in the first two years, defined as the need for respiratory medications (inhaled or systemic) at any time in this period.
Time frame: From the date of discharge from the hospital to 2 years of age
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.